There are 24 resources available
Patient selection and clinical outcomes of CDK4/6 inhibitors in HR+/HER2- early breast cancer
Presenter: Dejan Juric
Session: Novartis - Expanding evidence for CDK4/6 inhibitors in HR+/HER2- breast cancer: From clinical trials to clinical practice
Resources:
Webcast
Clinical guidance on use of CDK4/6 inhibitors in HR+/HER2- ABC
Presenter: Yoon-Sim Yap
Session: Novartis - Expanding evidence for CDK4/6 inhibitors in HR+/HER2- breast cancer: From clinical trials to clinical practice
Resources:
Webcast
Applying CDK4/6 inhibitor data to patient management in HR+/HER2- ABC
Presenter: Shusen Wang
Session: Novartis - Expanding evidence for CDK4/6 inhibitors in HR+/HER2- breast cancer: From clinical trials to clinical practice
Resources:
Webcast
Key takeaways and live Q&A
Presenter: Yoon-Sim Yap
Session: Novartis - Expanding evidence for CDK4/6 inhibitors in HR+/HER2- breast cancer: From clinical trials to clinical practice
Resources:
Webcast